English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance A large number of genetic alterations have been found in the cancer genome of lung adenocarcinoma. However, they need experimental validation to determine their tumorigenic potential, as well as the therapeutic utility of individual alterations. Here, we provide an shRNA-mediated screen to validate a large set of genes for their tumor suppressor efficacy in vivo in a mouse lung adenocarcinoma model. We identified several tumor suppressors, including ephrin receptor A2 (EphA2 ) loss of which promotes adenocarcinoma in the context of oncogenic mutantKRas mutation.EphA2 loss promotes cell proliferation by activating ERK MAP kinase signaling and hedgehog signaling pathways, leading to tumorigenesis. Identification of these pathways provides important therapeutic targets for lung adenocarcinoma.

Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma